Page 215 - Read Online
P. 215
Page 6 of 6 Zhong et al. Hepatoma Res 2019;5:18 I http://dx.doi.org/10.20517/2394-5079.2019.01
HBV-DNA levels: a randomized controlled trial. Ann Surg 2018;268:943-54.
34. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma
(HCC): a meta-regression approach. J Hepatol 2010;52:889-94.
35. Mo HY, Liao YY, You XM, Cucchetti A, Yuan BH, et al. Timely meta-analysis on the efficacy of adoptive immunotherapy for
hepatocellular carcinoma patients after curative therapy. PLoS One 2017;12:e0174222.
36. Zhong JH, Mo XS, Xiang BD, Yuan WP, Jiang JF, et al. Postoperative use of the chemopreventive vitamin K2 analog in patients with
hepatocellular carcinoma. PLoS One 2013;8:e58082.
37. Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol 2014;49:649-61.
38. Zhong JH, Zhong QL, Li LQ, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature
review. Tumour Biol 2014;35:9459-68.
39. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or
ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-54.
